Formycon AG and OneSource Specialty Pharma Limited announced a strategic manufacturing partnership for biosimilars, combining Formycon's development expertise with OneSource's end-to-end biologics manufacturing capabilities. Under the agreement, OneSource will provide integrated Drug Substance and Drug Product manufacturing from its state-of-the-art facility in Bangalore, India, to support Formycon's biosimilar programs for global markets.
Dr. Stefan Glombitza, CEO of Formycon AG, stated: "Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency. Together, we aim to broaden sustainable global access to life-changing biosimilar therapies."
Neeraj Sharma, Managing Director & CEO of OneSource Specialty Pharma, commented: "We are delighted to partner with Formycon, one of the world's leading biosimilar developers with a proven track record of bringing high-quality biosimilars to global markets. This partnership brings together Formycon's development expertise and OneSource's integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide. It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacturing of world-class biologics."
The partnership reflects a shared commitment to advancing global access to biosimilars through reliable, high-quality, and scalable manufacturing. Achieving this requires a sustainable, cost-effective manufacturing model—one that OneSource is specifically positioned to deliver. Formycon brings a strong track record in biosimilar development and commercialization, supported by an established portfolio and a robust pipeline. OneSource complements this with an integrated biologics platform spanning cell line development through commercial fill-finish, five manufacturing facilities approved by leading global regulatory authorities, including the US FDA and EMA, and extensive expertise across biologics, sterile injectables, and drug-device combinations.
This collaboration is particularly significant given the growing demand for biosimilars. As noted in the release, global sales of biosimilars currently amount to around 21 billion US dollars, with analysts projecting a rise to over 74 billion US dollars by 2030. The partnership aims to capitalize on this growth by ensuring cost-efficient production, which is critical for expanding patient access to these life-changing therapies. Formycon's FYB4Growth strategy emphasizes geographic diversification, a smart portfolio strategy, excellence and innovation, and consistent cost efficiency—all of which are supported by this manufacturing partnership.
For more information about Formycon, visit https://www.formycon.com. Details on OneSource can be found at www.onesourcecdmo.com.
